ARCHIVES

Phase II Study Meets Primary Endpoint, Demonstrating Overall Survival of 5.2 Months

This article is from The Cancer Letter archive.

Vol. 36 No. 9 | September 27, 2013

Download PDF Visit The Full Archive

Related Articles

Study: Routine CT Not Needed In Detecting DLBCL Remissions

May 31, 2013

NLST Suggests 18.5 Percent Of LDCT-Detected Cancers Could Be Indolent

December 27, 2013

Panel To Look At Cancer Centers Program, Starting With West Coast, Hawaii Meetings This Year, Next

January 27, 1984

ACS To Implement Cancer Response Systems Nationwide

August 2, 1985

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

December 2, 1983

Finasteride Raises Odds Of Finding Fast-Growing Cancers Early, Study Says

September 28, 2007